Trials / Unknown
UnknownNCT02738983
RT Plus EGFR-TKI for Wild-type NSCLC
Thoracic Radiotherapy Combined With EGFR-TKI for Wild-type Non-small Cell Lung Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 22 (estimated)
- Sponsor
- Hangzhou Cancer Hospital · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
Concurrent chemoradiotheray is the standard care for patients with locally advanced non-small cell lung cancer (NSCLC), but often accompanying with high toxicity and poor tolerability. Radiosensitization of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) has been proved in preclinical studies, and the safety of TKI combined with thoracic radiotherapy has also been evaluated in several phase II trials. The aim of study is to investigate the efficacy and safety of thoracic radiotherapy combined with TKI in wild-type EGFR patients who refused or unsuitable for concurrent chemoradiotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Erlotinib (trade name: Tarceva®) or Icotinib (trade name: Conmana®) | Erlotinib (trade name: Tarceva®) (150mg oral daily) or Icotinib (trade name: Conmana®) (125mg oral three times a day). |
| RADIATION | Radiotherapy | Concurrent radiotherapy total dose 60-66 Gy in 2 Gy fractions. One fraction per day, and 5 fractions per week. |
Timeline
- Start date
- 2012-01-01
- Primary completion
- 2016-12-01
- Completion
- 2017-12-01
- First posted
- 2016-04-14
- Last updated
- 2016-04-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02738983. Inclusion in this directory is not an endorsement.